Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Tests Blood In APAC; Goes For Deeper Penetration With NAT Tests

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Novartis Diagnostics dominated a large number of Western markets with its nucleic acid testing assays for donated blood, and now the Novartis unit is aiming to mirror that success in the Asia-Pacific region by aligning with private institutions, collaborating with progressive states in countries like India and working closely with non-governmental organizations

You may also be interested in...



In India, Roche Diagnostics Grows At Twice The Market Rate, But Public Awareness Still Low

MUMBAI - Roche Diagnostics India (Pvt) Ltd. Chairman and Managing Director Bhuvnesh Agarwal believes the company has benefited from the unprecedented surge in market growth, but still finds public awareness to be an issue when it comes to the most advanced diagnostics available to patients

In India, Roche Diagnostics Grows At Twice The Market Rate, But Public Awareness Still Low

MUMBAI - Roche Diagnostics India (Pvt) Ltd. Chairman and Managing Director Bhuvnesh Agarwal believes the company has benefited from the unprecedented surge in market growth, but still finds public awareness to be an issue when it comes to the most advanced diagnostics available to patients

Will World's Largest HCV Population Have Access To Newest Treatments?

With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel